Niro Narendran

Papers

1

Total Citations

12

H-Index

1

About

Dr. Niro Narendran is a leading ophthalmology researcher whose work centers on neovascular age-related macular degeneration (nAMD), a primary cause of blindness. His most significant contribution is the pivotal STAR trial, a randomized, double-masked, sham-controlled study evaluating stereotactic radiotherapy as a novel treatment for nAMD. This landmark 2024 trial, which has already garnered 12 citations, demonstrated that ionizing radiation can mitigate key pathogenic processes underlying the disease, offering a potential alternative or adjunct to the standard anti-VEGF injections. By rigorously testing this device-based approach, Dr. Narendran has advanced the field toward more durable, less invasive therapies for patients requiring frequent intraocular injections. His research addresses a critical unmet need in retinal disease management, and the STAR trial’s robust methodology sets a new benchmark for evaluating emerging treatments. With this work, Dr. Narendran has established himself as a key figure in the quest to reduce the treatment burden for nAMD patients worldwide.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
12 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 46

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago